Inovio Pharmaceuticals

NCT00721461

A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001)

NCT00685412

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

NCT01142362

Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults

NCT01188850

Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

NCT01184976

Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males

NCT01082692

Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants

NCT01403155

A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001

NCT01405885

A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus

NCT01587131

DNA-based Influenza Vaccine in the Elderly

NCT02027116

Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection

NCT02241369

Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies

NCT02960594

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

NCT02431312

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

NCT02464670

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

NCT02514213

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

NCT02670187

Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers

NCT02772003

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

NCT02809443

GLS-5700 in Dengue Virus-Naïve Adults

NCT02887482

GLS-5700 in Dengue Virus Seropositive Adults

NCT03674125

Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection

NCT03831503

A Study of INO-A002 in Healthy Dengue Virus-naive Adults

NCT03805984

Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers

NCT03835533

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

NCT04336410

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

NCT04093076

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana

NCT04367675

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

NCT04906629

INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees

NCT05293249

dMAbs for Prevention of COVID-19

NCT05430958

Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

NCT05781542

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV